Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as JZP926 capsule
JZP926 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| JZP926 Capsule | EXPERIMENTAL | Participants with JME will be randomized to JZP926 capsule based on weight-tiered dosing for a 16-week treatment period. |
| Placebo | PLACEBO_COMPARATOR | Participants with JME will be randomized to matching placebo based on weight-tiered dosing for a 16-week treatment period. |
| Open-Label Extension: JZP926 Capsule | EXPERIMENTAL | Participants completing Part A or Part B will have the option to continue into an open-label extension for up to 52 weeks, inclusive of a 4 week blinded transition. |
| Name | Type | Description |
|---|---|---|
| JZP926 capsule | DRUG | Oral administration BID according to body weight |
| Placebo | DRUG | Oral administration BID according to body weight |
Inclusion Criteria Participants are eligible to be included in the study only if all of the following criteria apply: 1. Is ≥ 10 years of age at the time of screening. 2. Has a diagnosis of JME per ILAE criteria as specified in the protocol. 3. Has at least 4 myoclonic seizure days per 28 days his...
JZP926 is an investigational small molecule being developed for the treatment of Juvenile Myoclonic Epilepsy, a form of epilepsy that typically begins in adolescence. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
JZP926 is being developed by Jazz Pharmaceuticals plc, a biopharmaceutical company traded on the NASDAQ under the ticker symbol JAZZ. The company is conducting clinical trials to evaluate the safety and efficacy of JZP926 for Juvenile Myoclonic Epilepsy.
JZP926 is in Phase 2 clinical development. It is an investigational drug and has not yet been approved by the FDA or any other regulatory agency. The ongoing Phase 2 trial is designed to evaluate its safety and efficacy in patients with Juvenile Myoclonic Epilepsy.
JZP926 is being studied in a Phase 2 clinical trial registered as NCT07723963. This randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of JZP926 capsules for the treatment of Juvenile Myoclonic Epilepsy. The trial is not yet recruiting and plans to enroll 260 participants in the United States.
Yes, JZP926 and JZP926 capsule refer to the same investigational drug. The capsule is the oral formulation being tested in clinical trials for Juvenile Myoclonic Epilepsy. The drug is being developed by Jazz Pharmaceuticals and is currently in Phase 2 testing.